Shenzhen New Industries Biomedical Engineering Co., Ltd. (SHE:300832)
China · Delayed Price · Currency is CNY 51.47
-0.40 (-0.77%)
Aug 24, 2026, 3:04 PM CST
SHE:300832 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,808 | 4,571 | 4,527 | 3,920 | 3,040 | 2,539 |
Other Revenue | 4.67 | 6.08 | 8.2 | 9.91 | 6.47 | 6.17 |
| 4,812 | 4,577 | 4,535 | 3,930 | 3,047 | 2,545 | |
Revenue Growth | 6.72% | 0.91% | 15.42% | 28.97% | 19.70% | 15.97% |
Cost of Revenue | 1,422 | 1,407 | 1,267 | 1,064 | 906.2 | 734.3 |
Gross Profit | 3,390 | 3,170 | 3,269 | 2,866 | 2,141 | 1,811 |
Selling, General & Admin | 859.76 | 863.66 | 839.96 | 736.09 | 463.67 | 537.29 |
Research & Development | 475.01 | 477.77 | 453.59 | 366.05 | 317.71 | 215.05 |
Other Operating Expenses | 70.12 | 37.56 | 16 | 15.25 | 12.49 | 8.57 |
Operating Expenses | 1,442 | 1,397 | 1,336 | 1,128 | 807.89 | 753.54 |
Operating Income | 1,948 | 1,773 | 1,933 | 1,739 | 1,333 | 1,058 |
Interest Expense | -0.5 | -0.53 | -0.42 | -0.43 | -0.27 | -0.15 |
Interest & Investment Income | 110.79 | 93.47 | 108.16 | 89.8 | 66.76 | 56.6 |
Currency Exchange Gain (Loss) | -101.83 | -14.66 | 18.64 | 17.71 | 68.98 | -31.3 |
Other Non Operating Income (Expenses) | -4.94 | -5.02 | -3.37 | -2.83 | -2.23 | -1.43 |
EBT Excluding Unusual Items | 1,951 | 1,846 | 2,056 | 1,843 | 1,466 | 1,081 |
Gain (Loss) on Sale of Investments | 23.45 | 19.77 | 28.94 | 18.55 | 15.62 | 18.76 |
Gain (Loss) on Sale of Assets | 0.03 | 0.03 | 0.04 | 0.05 | 0.62 | 0.1 |
Asset Writedown | -1 | -1.67 | -0.43 | -1.52 | -1.52 | -1.86 |
Other Unusual Items | -4.13 | -9.11 | 9.1 | 33.23 | 20.38 | 37.24 |
Pretax Income | 1,970 | 1,855 | 2,093 | 1,893 | 1,501 | 1,136 |
Income Tax Expense | 252.85 | 235.01 | 264.74 | 239.41 | 173.28 | 161.83 |
Net Income | 1,717 | 1,620 | 1,828 | 1,654 | 1,328 | 973.7 |
Net Income to Common | 1,717 | 1,620 | 1,828 | 1,654 | 1,328 | 973.7 |
Net Income Growth | 1.21% | -11.39% | 10.57% | 24.53% | 36.38% | 3.68% |
Shares Outstanding (Basic) | 785 | 786 | 786 | 785 | 785 | 784 |
Shares Outstanding (Diluted) | 785 | 786 | 786 | 786 | 786 | 786 |
Shares Change | -0.06% | 0.00% | -0.01% | -0.07% | 0.04% | 4.76% |
EPS (Basic) | 2.19 | 2.06 | 2.33 | 2.11 | 1.69 | 1.24 |
EPS (Diluted) | 2.19 | 2.06 | 2.33 | 2.10 | 1.69 | 1.24 |
EPS Growth | 1.27% | -11.39% | 10.59% | 24.61% | 36.32% | -1.03% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 1,640 | 1,211 | 917.24 | 1,096 | 559.17 | 430.28 |
Free Cash Flow Per Share | 2.09 | 1.54 | 1.17 | 1.40 | 0.71 | 0.55 |
Dividend Per Share | 1.200 | 1.200 | 1.300 | 1.000 | 0.700 | 0.600 |
Dividend Growth | -7.69% | -7.69% | 30.00% | 42.86% | 16.67% | -54.40% |
Gross Margin | 70.44% | 69.25% | 72.07% | 72.93% | 70.26% | 71.15% |
Operating Margin | 40.48% | 38.74% | 42.61% | 44.24% | 43.74% | 41.55% |
Profit Margin | 35.68% | 35.40% | 40.31% | 42.08% | 43.58% | 38.25% |
Free Cash Flow Margin | 34.07% | 26.46% | 20.22% | 27.89% | 18.35% | 16.90% |
EBITDA | 2,136 | 1,965 | 2,114 | 1,888 | 1,445 | 1,151 |
EBITDA Margin | 44.39% | 42.92% | 46.60% | 48.05% | 47.42% | 45.23% |
D&A For EBITDA | 188.28 | 191.52 | 181.07 | 149.58 | 111.87 | 93.64 |
EBIT | 1,948 | 1,773 | 1,933 | 1,739 | 1,333 | 1,058 |
EBIT Margin | 40.48% | 38.74% | 42.61% | 44.24% | 43.74% | 41.55% |
Effective Tax Rate | 12.84% | 12.67% | 12.65% | 12.65% | 11.54% | 14.25% |
Revenue as Reported | 4,812 | 4,577 | 4,535 | 3,930 | 3,047 | 2,545 |
Advertising Expenses | - | 69.71 | 73.75 | 58.54 | 34.34 | 20.25 |